These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35427194)

  • 1. Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater.
    Tran V; Tran H; Demirel S; Thompson-Moore N
    J Pharm Pract; 2023 Oct; 36(5):1125-1133. PubMed ID: 35427194
    [No Abstract]   [Full Text] [Related]  

  • 2. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of patient-specific factors contributing to effectiveness of glucagon-like peptide-1 receptor agonists.
    Mazzei KA; Trippett AN; Hedrick TD; Wen S
    J Am Pharm Assoc (2003); 2020; 60(6):937-942. PubMed ID: 32778515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world impact on monthly glucose-lowering medication cost, HbA
    Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
    J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON PATIENTS WITH DIABETES ON INSULIN THERAPY.
    Gyorffy JB; Keithler AN; Wardian JL; Zarzabal LA; Rittel A; True MW
    Endocr Pract; 2019 Sep; 25(9):935-942. PubMed ID: 31170363
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.
    Hall GC; McMahon AD; Dain MP; Wang E; Home PD
    Diabet Med; 2013 Jun; 30(6):681-6. PubMed ID: 23330649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
    Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA
    Henry RR; Rosenstock J; Denham DS; Prabhakar P; Kjems L; Baron MA
    Diabetes Care; 2018 Mar; 41(3):613-619. PubMed ID: 29301824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.